États-Unis - anglais - NLM (National Library of Medicine)

bachem americas, inc. - teriparatide acetate (unii: 9959p4v12n) (teriparatide acetate - unii:9959p4v12n) -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - teriparatide, quantity: 250 microgram/ml - injection, solution - excipient ingredients: metacresol; water for injections; sodium hydroxide; hydrochloric acid; glacial acetic acid; mannitol; sodium acetate trihydrate - terrosa is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.,terrosa is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - teriparatide - solution for injection - 250microgram/1ml

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - teriparatide - solution for injection - 250microgram/1ml

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

asahi kasei pharma corporation - teriparatide acetate - injection

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

mochida pharmaceutical co., ltd. - teriparatide(genetical recombination)[teriparatide biosimilar 1] - limpid and colorless injectable preparation

Malte - anglais - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - teriparatide - solution for injection in a pre-filled pen - teriparatide 20/80 µg/µl - calcium homeostasis

Irlande - anglais - HPRA (Health Products Regulatory Authority)

teva b.v. - teriparatide - solution for injection in pre-filled pen - 20/80 - parathyroid hormones and analogues; teriparatide

Union européenne - anglais - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporosis - calcium homeostasis - movymia is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

Union européenne - anglais - EMA (European Medicines Agency)

gedeon richter plc. - teriparatide - osteoporosis - calcium homeostasis - terrosa is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.